Bromomethyl acetate → 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-[acetoxymethyl]cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one
Reaction equation
[CH3:1][C:2]1[NH:10][C:9]2[C:8](=[O:11])[N:7]([CH3:12])[C:6]3=[N:13][C@@H:14]4[CH2:18][CH2:17][CH2:16][C@@H:15]4[N:5]3[C:4]=2[N:3]=1.[C:19]([O:22][CH2:23]Br)(=[O:21])[CH3:20]>>[CH3:1][C:2]1[N:10]([CH2:23][O:22][C:19](=[O:21])[CH3:20])[C:9]2[C:8](=[O:11])[N:7]([CH3:12])[C:6]3=[N:13][C@@H:14]4[CH2:18][CH2:17][CH2:16][C@@H:15]4[N:5]3[C:4]=2[N:3]=1Participants
3
Procedure
Treat 5,6a(R),7,8,9,9a(S)-hexahydro-2,5-dimethylcyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one from Example 19a with bromomethyl acetate in accordance with Example 47 to give the title compound as a powder.
Sources & evidence
- ORD record
- ord-b91dd292576a4b389e441bbb635cf326
- Source dataset
- uspto-grants-1995_02
- Patent number
- US05393755
Reaction notes
Loading…